A Study of BBI608 in Adult Patients With Advanced Colorectal Cancer
Status:
Completed
Trial end date:
2020-04-01
Target enrollment:
Participant gender:
Summary
This is an open label, multi-center, Phase 2 study of BBI608 in combination with cetuximab,
panitumumab or capecitabine in patients with advanced colorectal cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Boston Biomedical, Inc Sumitomo Dainippon Pharma Oncology, Inc